AG真人官方

TriSalus Life Sciences, Inc. (TLSI) filed an 8-K to report the successful completion of its exchange offer and related consent solicitation for its Series A Convertible Preferred Stock. The offer expired 23 Jul 2025; 3,551,502 preferred shares, or 98.82% of the class, were validly tendered. Holders will receive common shares equal to the sum of Liquidation Preference plus Accrued Dividends through 10 Aug 2027, divided by $4.00 per share. Settlement is targeted on or before 1 Aug 2025.

The overwhelming participation satisfied the required majority consent, allowing the company to adopt a Preferred Stock Amendment filed 24 Jul 2025 with the Delaware Secretary of State. The amendment authorizes TriSalus to mandatorily convert any remaining preferred shares after offer closing into common stock using the same exchange value, thereby eliminating the preferred class and its dividend obligations.

Key 8-K items invoked: 3.03 (material modification of rights), 5.03 (charter amendment), 5.07 (shareholder vote), 8.01 (other events). Exhibits include the amendment (3.1) and a press release (99.1) detailing final results.

TriSalus Life Sciences, Inc. (TLSI) filed Amendment No. 1 to its Schedule TO (Form SC TO-I/A) dated July 15, 2025. The amendment updates the documentation for the company鈥檚 issuer tender offer and related consent solicitation covering all outstanding shares of its Series A Convertible Preferred Stock.

Key terms reiterated:

• Each preferred share may be exchanged for common stock equal to (Liquidation Preference + accrued dividends through August 10, 2027) 梅 $4.00, subject to customary adjustment mechanisms.
• Concurrent consent solicitation seeks majority approval to amend the Certificate of Designations, enabling the company to mandatorily convert any remaining preferred shares at a conversion ratio 11.3% less favorable than the tender offer rate.

The amendment鈥檚 principal purpose is to replace the Prospectus/Offer to Exchange originally filed on June 23, 2025 with an updated version filed on July 11, 2025 as Exhibit (a)(1)(A) to Form S-4/A (File No. 333-288250). Other disclosures in the original Schedule TO remain unchanged.

Administrative details: The filing confirms the offer is an issuer tender offer under Rule 13e-4, is not a final amendment, and does not invoke cross-border exemptions. CEO Mary Szela signed the certification.

Pearl Diver Credit Company Inc. (NYSE: PDCC) filed a Form 8-K to disclose a single data point under Item 8.01 鈥� Other Events. Management has calculated the company鈥檚 unaudited net asset value (NAV) per common share at $18.19 as of June 30, 2025. No additional financial statements, earnings details, or transaction announcements were included. The filing is therefore informational, providing shareholders with an updated valuation reference ahead of future periodic reports.

TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 on 27-Jun-2025 for director Arjun J. Desai. On 12-Jun-2025 Desai received a grant of 15,000 non-qualified stock options at an exercise price of $5.50 per share. The options will fully vest on the earlier of (i) 12-Jun-2026 or (ii) the company鈥檚 next annual shareholder meeting, subject to continued service. They expire on 11-Jun-2035. After this grant, Desai beneficially owns 65,000 derivative securities; no common shares were acquired or sold, and ownership remains direct. The filing represents routine director compensation and does not disclose any open-market transactions.

Form 4 filing overview: On June 12 2025, TriSalus Life Sciences, Inc. (TLSI) granted Director Gary B. Gordon a non-qualified stock option covering 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on June 11 2035.

Vesting terms: The option will become fully vested on the earlier of (i) the one-year anniversary of the grant date (June 12 2026) or (ii) the date of TLSI鈥檚 next annual stockholder meeting, provided Mr. Gordon remains in service through such date.

Post-transaction ownership: Following the grant, Mr. Gordon beneficially owns 56,250 derivative securities (stock options) in TLSI, all held directly. No changes in non-derivative share ownership were reported.

Key takeaways for investors: 鈥� This is a routine incentive grant to a board member, aligning director compensation with shareholder interests.
鈥� No open-market purchases or sales were disclosed; therefore, the filing does not signal immediate sentiment regarding TLSI鈥檚 current share price.
鈥� The grant size is modest and is unlikely to have a material impact on the company鈥檚 capitalization or insider ownership structure.

Form 4 filing overview: On 06/12/2025, TriSalus Life Sciences, Inc. (TLSI) director Kerry R. Hicks was granted a non-qualified stock option for 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on 06/11/2035 and will vest in full on the earlier of 06/12/2026 or the company鈥檚 next annual shareholder meeting, subject to continued board service.

Following the grant, Mr. Hicks now beneficially owns 89,222 derivative securities (principally stock options). The filing indicates direct ownership; no indirect holdings were reported. No purchases or sales of common stock occurred, and the filing does not disclose any change to Mr. Hicks鈥� non-derivative share count.

The transaction was coded 鈥淎鈥� (acquisition), routine for director compensation, and was not executed under a Rule 10b5-1 plan. Because the filing relates only to an option grant鈥攚ithout an accompanying open-market trade鈥攊ts immediate market impact is typically limited. Nevertheless, investors may view the award as modest alignment of director incentives with shareholder interests through long-dated equity compensation.

Angel Oak Mortgage REIT, Inc. (NYSE: AOMR) filed an 8-K to disclose that, on June 24, 2025, it and two subsidiaries renewed their loan financing facility with 鈥淢ultinational Bank 1.鈥� The renewal follows the six-month rolling mechanism set out in the original Master Repurchase Agreement dated April 13, 2022.

The facility鈥檚 maturity was previously September 25, 2025 and is now extended to December 25, 2025, providing the REIT with an additional three months of secured funding capacity. No other terms鈥攕uch as borrowing limit, collateral eligibility, advance rates, or pricing鈥攚ere disclosed in the filing. Management characterizes the action as a routine extension; the disclosure is furnished under Item 8.01 and is not deemed 鈥渇iled鈥� for Exchange Act liability purposes.

While the incremental extension supports near-term liquidity and continuity of mortgage-loan purchasing activity, the short tenor highlights the company鈥檚 ongoing reliance on short-term repurchase (repo) financing. Investors should monitor future renewals and any material amendments to terms, especially as the December 2025 expiry approaches.

TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 reporting a routine equity award to director Sean Murphy. On 06/12/2025 Mr. Murphy was granted 15,000 non-qualified stock options with an exercise price of $5.50 per share. The award will fully vest on the earlier of one year from grant or the company鈥檚 next annual shareholder meeting, contingent on his continued service. The options expire on 06/11/2035. After the grant, the director beneficially owns 554,681 derivative securities (options) in aggregate. No shares of common stock were bought or sold; this filing solely reflects the incentive grant and therefore does not immediately affect the public float or insider ownership percentage.